$3 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 120 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMRSQ | Exit | IMRIS INC | $0 | – | -147,076 | -100.0% | -0.01% | – |
| ONTY | Exit | ONCOTHYREON INC | $0 | – | -143,200 | -100.0% | -0.01% | – |
| PTBIW | Exit | PLASMATECH BIOPHARMACEUTICAL*w exp 10/24/201 | $0 | – | -375,000 | -100.0% | -0.01% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -3,500 | -100.0% | -0.01% | – |
| HMSY | Exit | HMS HLDGS CORP | $0 | – | -29,900 | -100.0% | -0.02% | – |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -45,600 | -100.0% | -0.02% | – |
| AEZS | Exit | AETERNA ZENTARIS INC | $0 | – | -898,574 | -100.0% | -0.02% | – |
| ABT | Exit | ABBOTT LABS | $0 | – | -13,000 | -100.0% | -0.02% | – |
| AGRX | Exit | AGILE THERAPEUTICS INC | $0 | – | -105,000 | -100.0% | -0.03% | – |
| ALKS | Exit | ALKERMES PLC | $0 | – | -17,500 | -100.0% | -0.04% | – |
| PTBI | Exit | PLASMATECH BIOPHARMACEUTICAL | $0 | – | -349,908 | -100.0% | -0.04% | – |
| ILMN | Exit | ILLUMINA INC | $0 | – | -6,400 | -100.0% | -0.04% | – |
| PARNF | Exit | PARNELL PHARMACEUT HLDGS LTD | $0 | – | -253,592 | -100.0% | -0.04% | – |
| MEIP | Exit | MEI PHARMA INC | $0 | – | -802,568 | -100.0% | -0.05% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -49,400 | -100.0% | -0.05% | – |
| IMMU | Exit | IMMUNOMEDICS INCcall | $0 | – | -500,000 | -100.0% | -0.06% | – |
| SCMP | Exit | SUCAMPO PHARMACEUTICALS INCcl a | $0 | – | -225,000 | -100.0% | -0.11% | – |
| Exit | EXELIXIS INCnote 4.250% 8/1 | $0 | – | -4,985,000 | -100.0% | -0.12% | – | |
| RTRX | Exit | RETROPHIN INC | $0 | – | -158,223 | -100.0% | -0.12% | – |
| CCRN | Exit | CROSS CTRY HEALTHCARE INC | $0 | – | -366,724 | -100.0% | -0.14% | – |
| CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -473,588 | -100.0% | -0.15% | – |
| LMNS | Exit | LUMENIS LTD | $0 | – | -434,566 | -100.0% | -0.17% | – |
| CLLS | Exit | CELLECTIS S Asponsored ads | $0 | – | -150,506 | -100.0% | -0.17% | – |
| VSAR | Exit | VERSARTIS INC | $0 | – | -339,703 | -100.0% | -0.20% | – |
| KERX | Exit | KERYX BIOPHARMACEUTICALS INC | $0 | – | -765,450 | -100.0% | -0.32% | – |
| TRIV | Exit | TRIVASCULAR TECHNOLOGIES INC | $0 | – | -990,202 | -100.0% | -0.34% | – |
| TXMD | Exit | THERAPEUTICSMD INC | $0 | – | -2,223,310 | -100.0% | -0.44% | – |
| OVAS | Exit | OVASCIENCE INC | $0 | – | -407,108 | -100.0% | -0.46% | – |
| GILD | Exit | GILEAD SCIENCES INCput | $0 | – | -200,000 | -100.0% | -0.64% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS IN | $0 | – | -2,810,164 | -100.0% | -0.90% | – |
| Exit | INTEGRA LIFESCIENCES HLDGS Cnote 1.625%12/1 | $0 | – | -47,428,000 | -100.0% | -1.77% | – | |
| Exit | HORIZON PHARMA INCnote 5.000%11/1 | $0 | – | -16,014,461 | -100.0% | -2.53% | – | |
| AAVL | Exit | AVALANCHE BIOTECHNOLOGIES IN | $0 | – | -2,117,473 | -100.0% | -2.78% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -1,534,000 | -100.0% | -2.91% | – |
| ASPX | Exit | AUSPEX PHARMACEUTICALS INC | $0 | – | -4,449,103 | -100.0% | -14.45% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.